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Abstract
Cationic liposome-mediated intracellular delivery of a fluorescein-labeled chimeric DNA–RNA ribozyme targeted to the
HIV-1 5X LTR was investigated, using THP-1, THP-1rHIV-1 or HeLarLAV cells. Different fluorescence patterns wereIIIB
 .observed when the cells were exposed to Lipofectamine, Lipofectin or DMRIE:DOPE 1:1 complexed to the ribozyme.
With Lipofectamine intense cell-associated fluorescence was found. Incubation with Lipofectin resulted in less intense
diffuse fluorescence, while with DMRIE an intense but sporadic fluorescence was observed. Differentiated THP-1rHIV-1IIIB
cells were more susceptible to killing by liposome–ribozyme complexes than THP-1 cells. Under non-cytotoxic conditions
 .  .a 4-h treatment complexes of 5, 10 or 15 mM Lipofectin or DOTAP:DOPE 1:1 and ribozyme, at lipid:ribozyme ratios of
8:1 or 4:1, did not affect p24 production in THP-1rHIV-1 cells in spite of the intracellular accumulation of theIIIB
 .ribozyme. A 24-h exposure of THP-1rHIV-1 cells to 5 mM Lipofectin or DOTAP:DOPE 1:1 complexed with eitherIIIB
the functional or a modified control ribozyme reduced virus production by approximately 30%. Thus, the antiviral effect of
the liposome-complexed ribozyme was not sequence-specific. In contrast, the free ribozyme at a relatively high concentra-
tion inhibited virus production by 30%, while the control ribozyme was ineffective, indicating a sequence-specific effect.
Both Lipofectin and DOTAP complexed with ribozyme were toxic at 10 and 15 mM after a 24-h treatment. A 4-h treatment
of HeLarLAV cells with Lipofectin at 5, 10 or 15 mM was not toxic to the cells, but also did not inhibit p24 production. In
contrast, treatment of HeLa CD4q cells immediately after infection with HIV-1 at the same lipid concentrations andIIIB
lipid:ribozyme ratios was cytotoxic. Our results indicate that the delivery of functional ribozyme into cells by cationic
liposomes is an inefficient process and needs extensive improvement before it can be used in ex vivo and in vivo
applications. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .Ribozymes Rz are RNA molecules capable of
catalytically cleaving specific phosphodiester bonds
w xin complementary RNA molecules 1–4 . When de-
livered intracellularly, they can interfere with both
pre-integration and post-integration events of the HIV
replication cycle, by cleaving incoming viral RNA
w xand transcribed mRNAs 5 . Delivery of Rz to cells
 .has been attempted by i endogenous expression of
 .the Rz-encoding gene or ii exogenous delivery of
 .chemically-synthesized pre-formed Rz targeted to
w xhighly conserved regions of the virus 6 .
w xChang et al. 7 have demonstrated that an anti-
HIV-1 gag Rz can be expressed under the control of
the constitutive human b-actin promoter in HeLa
CD4q cells. The stable expression of this anti-gag
Rz in HeLa CD4q cells reduces gag transcripts and
w xp24 levels upon infection with HIV-1 1 . Since then,
many of the genetic elements of the retroviral genome
have been targeted including functional proteins,
leader sequences and regulatory protein sequences
w x2,8 . A hairpin Rz designed to cleave HIV-1 RNA in
the 5X leader sequence suppresses virus expression in
w xHeLa cells cotransfected with proviral DNAs 9,10 .
Human T-cell lines, primary T cells and CD34q
hematopoietic stemrprogenitor cells transduced with
retroviral vectors containing Rz were shown to be
resistant to challenge with diverse strains of HIV-1,
w xincluding uncloned clinical isolates 11–16 .
A number of problems need to be addressed before
pre-formed Rz can be used successfully for therapy:
 .i stabilization of the Rz against serum and cellular
nucleases without compromising its catalytic activity;
 .  .ii efficient delivery to the target cells; iii intra-
 .cellular localization of an active Rz; iv co-localiza-
tion of the Rz with its mRNA target inside cells. In
contrast to endogenous expression, exogenous deliv-
 .ery permits the use of chemically modified Rz MRz
which are more resistant to degradation by nucleases,
w xwhile maintaining cleavage capability 17,18 .
Chimeric DNA–RNA hammerhead Rz, with DNA in
helices I and III, have an increased resistance to
nucleases and a six-fold greater catalytic activity than
w xan analogous all-RNA Rz 19 .
Several cationic liposome formulations have been
w xdeveloped to facilitate delivery of DNA 20–23 ,
w xmRNA 24 and antisense oligonucleotides into eu-
w xkaryotic cells 25–30 . In the present study we evalu-
ated the intracellular delivery and anti-HIV effect of
a fluorescein-labeled chimeric DNA–RNA Rz tar-
geted to the HIV-1 5X LTR, using four cationic
liposomal preparations. Lipofectamine, Lipofectin,
wand liposomes composed of either DMRIE:DOPE a
 .1:1 wrw mixture of 1,2-dimyristyloxypropyl-3-di-
 .methyl-hydroxyethylammonium bromide DMRIE
.  .x and DOPE : dioleoylphosphatidylethanolamine 1:1,
. w   .wrw or DOTAP:DOPE N- 1- 2,3-dioleoyloxy pro-
.x pyl-N, N, N-trimethylammonium propane 1:1,
.wrw , were complexed with the Rz and added to
cultures of differentiated monocytic THP-1 cells and
chronically infected THP-1rHIV-1 cells, as wellIIIB
as chronically and de novo infected HeLa CD4q
cells. Differentiated THP-1 and THP-1rHIV-1IIIB
cells were used in our study because they represent a
convenient model of monocyte-derived macrophages
w x w x31 and chronically infected macrophages 32,33 ,
respectively. Because HeLa cells are often used as a
model system for cationic liposome-mediated DNA
delivery, chronically infected HeLarLAV cells and
de novo infected HeLa CD4q cells were also in-
cluded in our study. Some of our results have been
w xpresented earlier in preliminary form 34,35 .
2. Materials and methods
2.1. Materials
LipofectAMINEe reagent and Lipofectin reagent
were obtained from GIBCO BRL Life Technologies,
 . w xGaithersburg, MD . LipofectAMINEe reagent 36
contains the polycationic lipid 2,3-dioleyloxy-
w  . xN 2 sperminecarboxamido ethyl -N, N -dimethyl-1-
 .propanaminium trifluoroacetate DOSPA and the
 .neutral lipid, DOPE 3:1, wrw . Lipofectin reagent
w x w 20 contains the monocationic lipid N- 1- 2,3 dioley-
. xloxy -propyl -N,N,N-trimethylammonium chloride
 .  .DOTMA and DOPE 1:1, wrw . DMRIE reagent
w x  .37 was synthesized by VICAL San Diego, CA .
Small unilamellar liposomes composed of DOTAP
 .and DOPE 1:1, wrw were prepared in our labora-
w xtory 38 . Alamar Blue dye was purchased from
 .Alamar Biosciences Sacramento, CA . DOTAP and
DOPE were obtained from Avanti Polar Lipids
 .Alabaster, AL . Penicillin, streptomycin and L-
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glutamine were obtained from Irvine Scientific Santa
.Ana, CA . PBS was obtained from Zymed Laborato-
 .ries South San Francisco, CA .
A 38-mer, 5X fluorescein-labeled, chimeric DNA–
RNA hammerhead Rz with two phosphorothioate
X  .linkages at the 3 terminal mol. wt. 12,519.2 , was
targeted to the HIV-1 5X LTR. The catalytic activity
of the Rz was first tested in a cell-free system. A
control Rz with a scrambled sequence in the binding
 .arms was also designed and synthesized MRz . The
sequences of these Rz are as follows:
Rz: 5X-ACACAACAcugaugaGTCCGTGAG-
GACgaaaCGGGC)A)C-3X
MRz: 5X-CAAACAACcugaugaGTCCGTGAG-
GACgaaaACCGG)G)C-3X
where the ‘)’ indicates a phosphorothioate inter-
nucleotide linkage, capital letters represent deoxy-
ribonucleotides and lowercase letters represent ribo-
nucleotides.
The mixed oligodeoxyribo- and ribonucleotides
were synthesized on an automated synthesizer Ap-
.plied Biosystems 394 RNArDNA as described pre-
w xviously 19 .
2.2. Cells and ˝irus
THP-1 cells were obtained from the American
 .Type Culture Collection TIB-202 . A chronically
 .HIV-infected cell line designated THP-1rHIV-1IIIB
was developed in our laboratory by infecting THP-1
cells with HIV-1 at a low multiplicity of infectionIIIB
w x31 , and the clone designated as THP-1r wasIIIB30
w xused in further experiments 39 . Cells were main-
tained at 378C, under 5% CO in RPMI 1640 medium2
 .supplemented with 10% vrv heat-inactivated FBS
 .  .fetal bovine serum Sigma; St. Louis, MO
 .  .RPMIr10 , penicillin 100 unitsrml , streptomycin
 .  .100 mgrml and L-glutamine 2 mM . The cells
were passaged 1:6 once a week.
HeLarLAV and HeLa CD4q were obtained
through the AIDS Research and Reference Reagent
Program Division of AIDS, NIAID, NIH, Bethesda,
. w xMD from Drs. Joerg Berg and Matthias Wabl 40
w xand Dr. Richard Axel 41 , respectively. HeLarLAV
cells were maintained at 378C, under 5% CO in2
DME-HG Dulbecco’s Modified Eagle’s Medium,
.  .high glucose Irvine Scientific supplemented with
 .  .10% FBS DMEr10 , penicillin 100 unitsrml ,
 .  .streptomycin 100 mgrml and L-glutamine 4 mM .
HeLa CD4q cells were grown in RPMI 1640 medium
 .with 10% FBS, penicillin 100 unitsrml , strepto-
 .  .mycin 100 mgrml , L-glutamine 2 mM and 0.6
 .  .mgrml Geneticin G418 sulfate GIBCO . The cells
were passaged 1:20 once a week. Flow cytometric
analysis indicated that over 90% of cells were CD4-
positive.
The presence of cell surface CD4 was examined
by direct immunofluorescence assay, using fluores-
 .cein isothiocyanate FITC -conjugated Leu3 antibody
 .Becton-Dickinson , with FITC-conjugated mouse
IgG as a control. The fluorescence distribution was
analyzed with a fluorescence-activated cell sorter
 .FACScan; Becton-Dickinson, Mountain View, CA .
2.3. Treatment with liposome–Rz complexes
Uninfected monocytic THP-1 cells and chronically
 6infected THP-1rHIV-1 cells 1 ml at 1=10IIIB
.cellsrml were plated in 48-well plates, treated with
 . w x160 nM phorbol 12-myristate 13-acetate PMA 37
for 24 h at 378C, and exposed to liposome–Rz com-
plexes 5 or 6 days post-differentiation. HeLarLAV
 5cells were plated in 24-well plates 2=10 cellsr2
.ml and treated after 48 h, at ;60% confluency, in
the absence or presence of 8% FBS.
 .LipofectAMINEe reagent LFA was provided at
 .0.5 mM corresponding to 2 mgrml and Lipofectin
 . reagent LF was provided at 0.68 mM correspond-
. ing to 1 mgrml . DMRIErDOPE referred to as
.DMRIE in the rest of the paper was prepared to
0.747 mM in sterile water, corresponding to 1 mgrml.
 .DOTAPrDOPE referred to as DOTAP was pre-
 .pared at 0.71 mM corresponding to 1 mgrml .
Lyophilized fluorescent Rz was stored at 48C, dis-
solved in 10 mM Tris, 1 mM EDTA, 0.1 M NaCl
buffer, pH 8.0, and then diluted in the appropriate
medium without serum or antibiotics.
For all experiments, the indicated amounts of lipid
and Rz were complexed for 30 min at room tempera-
ture in RPMI or DME-HG medium without serum or
antibiotics. Meanwhile the cells were washed twice
with 1 ml medium, and 0.4 ml of medium was placed
on each well. The lipid–Rz mixture was then added
gently in a volume of 0.1 ml per well. The mixture
remained on the cells for 4 h or 24 h at 378C in a 5%
CO incubator. Cells treated with either medium or2
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Rz alone served as controls. Following treatment,
cells were washed with PBS and viewed by phase
contrast and fluorescence microscopy, using a Nikon
Diaphot microscope Nikon Instrument Group;
.Melville, NY . Cell morphology was evaluated by
inverted phase contrast microscopy at 250= or 400=
magnification. Photographs of fluorescence and
phase-contrast fields were made on Fuji color print
 .film at ISO ASA 1600 or on Kodak black and white
print film at ASA 400. The treated cells were fed
every 2–3 days with fresh medium RPMIr10 for
THP-1 and HeLa CD4q cells, or DMEr10 for
.HeLarLAV cells and incubated for the indicated
periods of time before the Alamar Blue assays and
monitoring of the p24 level in supernatants. p24
values represent the amount of virus produced in
.ngrml between the time of medium change and the
time of p24 determination. This time period is indi-
cated in the figure legends. Results were compared to
medium-treated controls. Statistical significance was
evaluated by the unpaired Student’s t-test, using
 .StatView software BrainPower, Calabasas, CA . p
values of F0.05 were taken to indicate a significant
difference.
2.4. HIV infection of HeLa CD4q cells
The virus and infected cells were handled in a
BL-3 facility. HeLa CD4q cells were plated in 12-
well plates at 2=105 cellsrwell, and on the next
day, at ;50% confluency, they were exposed to
HIV-1 for 2 h at 378C, at 5=103 TCID perIIIB 50
well. Following infection, the cells were washed to
remove unbound virus and were treated with lipo-
some–Rz complexes or medium alone. Control cells
were treated similarly but not exposed to virus. The
infection was monitored by determining viral p24 in
culture supernatants by an antigen capture ELISA
w x assay 42 , using a Molecular Devices Menlo Park,
.CA V microplate reader.max
The supernatant of chronically infected
H9rHTLV-IIIB cells was used as a source of the
HIV-1 strain, HIV-1 . The culture supernatantsIIIB
were harvested at times of peak p24 production and
stored at y808C. The p24 concentration of the stock
was 1.4 mgrml as determined by ELISA. The tissue
 .culture infectious dose, 50% endpoint TCID , was50
determined as described by Johnson and Byington
w x 343 . The infectious titer per 1 mg p24 was 7.1=10
TCID .50
2.5. Cell ˝iability assay
The number of viable cells used for experiments
was determined by Trypan Blue exclusion. Cell via-
bility after treatment with free or liposome-com-
plexed Rz was quantified by a modified Alamar Blue
w x  .assay 44 . Briefly, 1.0 ml of 10% vrv Alamar Blue
dye in the appropriate medium was added to each
well. After incubation for various times described
.under figure legends at 378C, 200 ml of the super-
natant was collected from each well and transferred
to 96-well plates. The absorbance at 570 nm and 600
nm was measured with a microplate reader. Cell
viability as a percentage of mock-treated control
. cells was calculated according to the formula, A570
.  .yA of test cells=100r A yA of control600 570 600
cells. After removal of the Alamar Bluermedium
mixture, fresh growth medium was added, and cells
were returned to the incubator. Thus, the Alamar
Blue assay allows determination of viability over the
culture period without the detachment of adherent
cells. A good correlation was obtained between the
w xAlamar Blue assay and Trypan Blue staining 39 .
3. Results
3.1. Deli˝ery of liposome–Rz complexes to unin-
fected, differentiated THP-1 cells
Differentiated THP-1 cells were exposed to the
liposome–Rz complexes for 4 or 24 h in RPMI
medium with 8% FBS. The cells were exposed to
Lipofectamine at 3 or 8 mM, and to Lipofectin and
DMRIE at 15 or 40 mM, complexed with Rz, at a
 .lipid:Rz wrw ratio of 1.3:1. Under these condi-
 .tions, the charge ratio qry for Lipofectamine
was 1.7, while for Lipofectin and DMRIE this ratio
was about 0.3. Thus, a net positive charge was not
absolutely required for the complex to be taken up.
Different fluorescence patterns were observed with
the three liposomal preparations. With Lipofec-
tamine, intense cell-associated fluorescence was
found. Treatment with Lipofectin resulted in less
intense diffuse fluorescence, while with DMRIE, an
intense but sporadic fluorescence was observed Figs.
.1 and 2 . The Rz alone, at concentrations of 12 to 40
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 .  X X.Fig. 1. Fluorescence A–D and phase contrast A –D micrographs of differentiated uninfected THP-1 cells treated for 4 h with LFA at 3
 .  .  .  .  .mM A or 8 mM B , and LF C or DMRIE D at 40 mM, complexed with Rz, at a lipid:Rz wrw ratio of 1.3:1.
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 .  X X.Fig. 2. Fluorescence A–D and phase contrast A –D micrographs of differentiated uninfected THP-1 cells treated for 24 h with LFA at
 .  .  .  .  .3 mM A or 8 mM B , and LF C or DMRIE D at 40 mM, complexed with Rz, at a lipid:Rz wrw ratio of 1.3:1.
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Fig. 3. Effect of LFA, LF or DMRIE complexed with Rz on the
viability of differentiated, uninfected THP-1 cells. PMA-treated
THP-1 cells, 5 days post-differentiation, were exposed to the
 .liposome–Rz complexes LFA: Lipofectamine, LF: Lipofectin
 . or the Rz alone 40 mgrmls3.2 mM for 4 or 24 h see Section
.2 for details . Cell viability was measured on day 13 for the 4-h
treatment, and on day 12 for the 24-h treatment, by incubating
the cells with Alamar Blue overnight at 378C. The viability is
expressed as percent of the control. Data represent the mean"
standard deviation obtained from duplicate wells.
 .mgrml 0.96 to 3.2 mM , showed no significant
 .cellular accumulation data not shown . The cells
were further incubated and fed every 2–3 days with
RPMIr10 medium before cell viability was quanti-
fied on days 12 or 13 post-treatment. The only cyto-
toxic treatment was that with 8 mM Lipofectamine
 .which caused disintegration of the cells Fig. 3 .
3.2. Deli˝ery of liposome–Rz complexes to differenti-
ated THP-1rHIV-1 cellsIIIB
Differentiated THP-1rHIV-1 cells were ex-IIIB
posed to Lipofectamine at 3 mM, and to Lipofectin
or DMRIE at 15 mM, complexed with Rz, at a
 .lipid:Rz wrw ratio of 4:1 or 1.3:1. Micrographs
were taken following a 4-h treatment in RPMI
medium with 8% FBS. The fluorescence patterns
obtained with the three liposomal preparations were
similar to that described for differentiated THP-1
 .cells data not shown . The cells were further incu-
bated and fed every 2 days with fresh RPMIr10
medium; viral p24 production was measured on days
2, 4, 6 and 8. Only 3 mM Lipofectamine was cyto-
toxic at the ratio of 1.3:1, causing disintegration of
 .the cells and inhibition of p24 production Fig. 4B .
At the ratio of 4:1, the cationic liposome–Rz com-
plexes were not toxic and did not inhibit p24 produc-
 .tion Fig. 4A .
Because transfection with Lipofectin resulted in
diffuse cytoplasmic fluorescence further experiments
were performed with this lipid as well as with its
analog DOTAP which has acyl instead of alkyl chains.
Differentiated THP-1rHIV-1 cells were treatedIIIB
with Lipofectin or DOTAP at 5, 10 or 15 mM,
 .complexed with Rz, at a lipid:Rz wrw ratio of 8:1
 .or 4:1, or Rz alone at 5.5 mgrml 0.44 mM . The
 .Fig. 4. The effect of Rz, complexed with LFA 3 mM , LF or
 .DMRIE both 15 mM , on p24 production in differentiated
THP-1rHIV-1 cells. Differentiated THP-1rHIV-1 cells inIIIB IIIB
48-well plates, 6 days post-differentiation, were exposed to the
 .liposome–Rz complexes LFA: Lipofectamine, LF: Lipofectin ,
 .  .  .at lipidrRz ratios of 4:1 wrw A or 1.3:1 B , or the Rz alone
 .  .at 15 mgrml 1.2 mM , for 4 h see Section 2 for details . Viral
p24 antigen production within the previous 48-h period was
determined on days 2, 4, 6 and 8. Data represent the mean"
standard deviation of p24 determinations in duplicate, in super-
 .natants of duplicate wells ns4 .
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 .charge ratio qry for the 8:1 complex was 1.8
while for the 4:1 complex this ratio was 0.9. Follow-
ing a 4 or 24-h treatment in RPMI medium with 8%
FBS, micrographs were taken. After a 4-h treatment,
p24 production was determined on days 3, 5, 7, 9 and
14, and cell viability was measured on day 14. After
a 24-h treatment, p24 production was determined on
days 2, 4 and 6, and cell viability was measured on
day 6. A concentration-dependent, cell-associated dif-
fuse fluorescence was observed after a 4-h treatment.
However, neither Lipofectin- nor DOTAP–Rz com-
plexes reduced cell viability or affected p24 produc-
 .tion after a 4-h treatment data not shown .
A 24-h exposure to 5 mM Lipofectin or DOTAP
 .complexed with Rz, at a lipid:Rz wrw ratio of 8:1
 .or 4:1, reduced the p24 levels at day 2 Fig. 6 .
Fluorescence patterns observed with DOTAP are
shown in Fig. 5. At Lipofectin:Rz ratios of 8:1 or 4:1,
 .  X X. Fig. 5. Fluorescence A–C and phase contrast A –C micrographs of differentiated THP-1rHIV-1 cells treated with free Rz 5.5IIIB
.  .  .  .  .mgrmls0.44 mM A , and 5 mM DOTAP at a lipid:Rz wrw ratio of 8:1 B or 4:1 C for 24 h.
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 .  .Fig. 6. Effect of LF A or DOTAP B complexed with Rz on
p24 production in differentiated THP-1rHIV-1 cells. PMA-IIIB
treated THP-1rHIV-1 cells, 6 days post-differentiation, wereIIIB
 .exposed to the liposome–Rz complexes, at lipid:Rz ratios wrw
 .of 8:1 or 4:1, or the Rz alone at 5.5 mgrml 0.44 mM , for 24 h
 .see Section 2 for details . The p24 antigen production within the
previous 48-h period was measured on days 2 and 4. Data
represent the mean"standard deviation of p24 determinations in
 .duplicate, in supernatants of duplicate wells ns4 except in
 .controls which were measured in five wells. Asterisks ) indi-
cate that the values were significantly different from the un-
treated controls. LF and DOTAP at 10 and 15 mM were cyto-
toxic.
the p24 levels were reduced by 32.5% or 39.4%,
respectively. These values were significantly lower
than the untreated controls 0.005-pF0.01, or pF
.0.005, respectively . With the DOTAP:Rz complex at
the ratio of 8:1 or 4:1, the p24 levels were reduced by
48.6% or 31.2%, respectively. These values were
significantly lower than the untreated controls pF
.0.005, or 0.005-pF0.01, respectively . At this lipid
 .concentration 5 mM , the lipid:Rz ratio of 8:1 corre-
 .sponds to 0.93 mg Rzrml 0.074 mM and the 4:1
 .ratio corresponds to 1.9 mg Rzrml 0.15 mM . When
cells were treated for 24 h with free Rz, at 5.5
 .mgrml 0.44 mM , the p24 level was reduced by
23.7% compared to untreated controls 0.01-pF
.0.025 . On day 4 and 6 the p24 values were signifi-
cantly lower only with the Lipofectin:Rz complex at
 .  .the ratio of 4:1 Fig. 6A day 6; data not shown .
The p24 levels were reduced by 25.4% 0.005-pF
.  .0.01 and 19.1% 0.025-pF0.05 on day 4 and 6,
respectively. Thus, on day 2 virus production was
reduced to a greater extent by the liposome-com-
plexed Rz than by a three to six-fold higher concen-
tration of free Rz. This concentration of free Rz
corresponded to the Rz added with lipid:Rz complex
at 15 mM lipid at the ratio 4:1. Therefore, liposome-
mediated delivery of the Rz enhanced its anti-HIV
effect, as determined by reduction of p24 levels on
day 2. However, treatment with the Lipofectin:Rz
 .  .8:1 and DOTAP:Rz 8:1 and 4:1 complexes could
not prevent virus production from increasing over
time. On days 4 and 6, the level of p24 antigen
produced within the previous 48-h period was similar
in the treated and control wells. Under the same
conditions, both liposomal preparations at 10 and 15
mM were highly cytotoxic, causing substantial disin-
 .tegration of the cells data not shown and a decrease
 .in p24 levels Fig. 6 .
To determine whether the modest inhibitory effect
observed at 5 mM lipid concentration was sequence-
specific, differentiated THP-1rHIV-1 cells wereIIIB
exposed to 5 mM Lipofectin or DOTAP complexed
with the functional Rz, or with control MRz Table
.1 . When cells were treated for 24-h with free Rz at
 .5.5 mgrml 0.44 mM , the p24 level was reduced by
 .30.7% compared to untreated controls pF0.005 .
Under the same conditions MRz was not inhibitory.
However, both Rz and MRz were equally inhibitory
when they were complexed with cationic liposomes.
For example, Lipofectin complexed with Rz or MRz
at a ratio of 8:1 reduced the p24 levels by 30%
 .pF0.005 . Under the same conditions DOTAP
complexed with Rz or MRz reduced the p24 levels
 .  .by 34.5% pF0.0005 or 28.5% pF0.005 , re-
spectively.
 .Interestingly, the charge ratios qry for the 8:1
and 4:1 complexes are 1.8 and 0.9, respectively.
Thus, it appears that the functional delivery of Rz in
the 4:1 complex is not dependent on the presence of a
net positive charge on the complex. However, it is
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Table 1
Effect of LF and DOTAP complexed with anti-LTR or MRz on p24 production in differentiated THP-1rHIV-1 cellsaIIIB
 .Treatment p24 ngrml
Free Rz LF:Rz DOTAP:Rz
8:1 4:1 8:1 4:1
bNone 3.68"0.43 y y y y
Anti-LTR Rz 2.55"0.14 2.58"0.23 3.15"0.23 2.41"0.05 2.21"0.23
MRz 3.81"0.36 2.54"0.09 2.69"0.27 2.63"0.11 3.11"0.17
a  .PMA-treated THP-1rHIV-1 cells, 6 days post-differentiation, were exposed to the liposome–Rz complexes, at lipid:Rz ratios wrwIIIB
  . .  .of 8:1 or 4:1 0.93 and 1.9 mg Rzrml 0.074 and 0.15 mM , respectively , or the Rz alone at 5.5 mgrml 0.44 mM , for 24 h. The p24
production within the previous 48-h period was measured on day 2. Data represent the mean"standard deviation of p24 determinations
 .in duplicate, in supernatants of duplicate wells ns4 , except in controls which were measured in three wells.
bUntreated controls.
possible that positively charged regions of the com-
plexes mediate their attachment to the cells.
3.3. Deli˝ery of liposome–Rz complexes to chroni-
cally infected HeLarLAV cells
Chronically infected HeLarLAV cells were ex-
posed to Lipofectin at 5, 10 and 15 mM, complexed
 .with Rz, at a lipid:Rz wrw ratio of 8:1 or 4:1 in
DME medium with 8% FBS. Micrographs were taken
following a 4-h treatment at 378C. The cells were
further incubated and fed every day with fresh
DMEr10 medium; p24 production was measured on
days 1, 2 and 3. Although a concentration-dependent,
cell-associated diffuse fluorescence was observed, the
treatment did not affect p24 production, nor did it
 .cause cytotoxicity data not shown .
3.4. Deli˝ery of liposome–Rz complexes to de no˝o-
infected HeLa CD4qcells
One explanation for the lack of inhibition of p24
production in HeLarLAV cells by liposome–Rz
complexes is that the efficiency of delivery was too
low to affect significantly the level of p24 antigen in
culture supernatants of cells producing high quanti-
ties of virus. Therefore, we next examined if p24
production could be reduced by Lipofectin–Rz com-
plexes in de novo infected HeLa CD4q cells, produc-
ing much lower levels of virus.
HeLa CD4q cells were infected with HIV-1 atIIIB
5=103 TCID per well, as described in Section 2.50
Immediately after infection the cells were exposed to
Lipofectin at 5, 10 and 15 mM, complexed with Rz,
 .at a lipid:Rz wrw ratio of 4:1 for 4 h in RPMI
medium with 8% FBS. On 1 and 2 days post-treat-
ment, the culture medium was replaced with fresh
medium, and 3 days later the culture supernatants
were analyzed for viral p24. Under these conditions
treatment of de novo infected HeLa CD4q cells with
the Lipofectin–Rz complexes was cytotoxic while the
 .Rz alone was not toxic Fig. 7 . A similar cytotoxic
effect was observed when uninfected HeLa CD4q
Fig. 7. Effect of LF complexed with Rz on p24 production in de
novo infected HeLa CD4q cells. The cells were exposed to the
 .LF–Rz complexes at a lipid:Rz ratio wrw of 4:1, or to the Rz
 . alone at 5.5 mgrml 0.44 mM , for 4 h see Section 2 for
.details . The p24 antigen production within the previous 72-h
period was measured on day 5 and was expressed as percent of
 .the control 100%s0.56"0.11 ng p24rml . Cell viability was
measured on day 5 post-infection incubation with Alamar Blue
.for 90 min at 378C and was expressed as percent of the control.
Data represent the mean"standard deviation obtained from du-
plicate wells or quadruplicate control wells.
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cells were incubated with the Lipofectin–Rz com-
 .plexes data not shown .
4. Discussion
 .Our results demonstrate that i treatment with
liposome–Rz complexes results in cell-associated flu-
 .orescence in a concentration-dependent manner; ii
different cellular fluorescence patterns are observed
with the four cationic liposomal preparations Lipo-
.  .fectamine, Lipofectin, DMRIE and DOTAP ; iii
treatment of THP-1rHIV-1 cells with both func-IIIB
tionally active or MRz complexed with 5 mM Lipo-
fectin or DOTAP for a 24-h period causes a reduction
 .in HIV production; iv differentiated chronically in-
fected THP-1rHIV-1 cells are more susceptible toIIIB
killing by liposome–Rz complexes than uninfected
 .THP-1 cells; v CD4-expressing HeLa cells are more
susceptible to killing by liposome–Rz complexes than
chronically infected HeLarLAV cells.
Compared to the wide variety of methods used to
deliver DNA, progress in introducing RNA molecules
into cells has been slow, probably because of the
rapid degradation of RNA by both exo- and endo-
w xribonucleases 24 . Only a few studies have reported
results obtained with exogenous delivery of Rz. In
one study polybrene-treated H9 cells were incubated
with 1 or 100 mM anti-HIV-1 gag Rz and subse-
w xquently infected with HIV-1 45 . The formation of
syncytia was assessed 7 days after infection. The Rz
inhibited the formation of syncytia by 9% and 67%,
at 1 and 100 mM, respectively, when compared to
untreated controls. These results suggest that the
exogenous administration of anti-HIV-1 Rz may be
effective in blocking viral infection in H9 cells.
However, the pre-formed Rz RNAs were short-lived,
and 5 h after addition no intact Rz RNAs could be
detected inside the cells. In a subsequent study, the
 .anti-HIV-1 gag Rz 142 nucleotides in length was
encapsulated in liposomes composed of 50 mol%
dipalmitoylphosphatidylglycerol. This procedure en-
hanced the uptake and protected the RNA molecules
w xfrom degradation over a 48-h period in H9 cells 2 .
Similarly, encapsulation of an all-RNA Rz in lipo-
somes containing dimyristoylphosphatidylglycerol
 .DMPG , phosphatidylethanolamine and cholesterol,
or cardiolipin, phosphatidylcholine and cholesterol
increased its resistance to serum ribonucleases for at
least 24 h and enhanced the accumulation of Rz in
HepG2 cells to up to 1.5% of the added dose after 24
w xh 30 .
Cationic liposomes as an exogenous delivery sys-
tem for Rz have likewise been described in only a
few studies. In one study chimeric DNA–RNA Rz
complexed with Lipofectin were shown to be more
stable in H9 cells over a 48-h period than their
w xall-RNA counterparts 19 . Lipofectin was also used
to deliver hammerhead Rz targeted to human uroki-
nase receptor mRNA, into human osteosarcoma cells
w x46 . While free Rz were degraded immediately in
medium, Rz complexed with Lipofectin were stable
for up to 22 h and were efficiently transported into
the cytoplasm. Another cationic liposome formula-
 .tion, Transfectam lipopolyamine , was used to de-
liver a chimeric hammerhead Rz directed against
 .bcr-abl mRNA, to a cell line EM-2 derived from a
w xpatient with chronic myelogenous leukemia 47 . The
Rz decreased the level of bcr-abl mRNA and inhib-
ited expression of the bcr-abl gene product, as well
as cell growth. A multi-unit Rz that targets bcr-abl
mRNA was delivered into murine myoloblasts trans-
 .formed with the bcr-abl gene 32D cells , using
w xeither Lipofectin or folic acid–polylysine 48 . Both
delivery systems protected Rz from degradation in
serum-free-medium up to 24 h and enhanced Rz
uptake; however, the folate receptor-mediated uptake
was up to 10-fold more efficient than that mediated
by Lipofectin. Another cationic lipid, DOTAP, was
used to deliver hammerhead Rz targeted to the MDR-
1 mRNA, into human pleural mesothelioma cells
w x49 . A 42-mer chimeric DNA–RNA hammerhead Rz
targeted to a leukocyte-type 12-lipoxygenase mRNA,
was delivered into porcine aortic vascular smooth
muscle cells after complexation with Transfectam
w x50 . The Rz almost completely inhibited specific
mRNA expression at 4 mM, but appeared to be
ineffective at 0.5 mM. We should note that the use of
Rz concentrations in the range 0.5–4 mM in our
experiments would have been toxic to the cells.
Our results indicate that cationic liposome–Rz
complexes are readily taken up by differentiated
THP-1rHIV-1 cells. However, in spite of theIIIB
intracellular accumulation of the Rz, its effect on
virus production is confined to a very limited set of
non-cytotoxic conditions. The lack of specific inhibi-
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tion by the liposome-complexed functional Rz vs. the
MRz may be explained by a non-specific oligo-
nucleotide effect. In contrast, the free MRz did not
inhibit p24 production when compared with the free
 .functional Rz Table 1 . Since the functionally active
chimeric Rz have been effective against cellular tar-
w xgets 19 , the lack of major efficacy against HIV is
most likely due to the inability of the Rz to enter the
cytoplasm in sufficient quantities to inhibit virus
production. It is also not clear what fraction of the Rz
is free to interact with substrate, and what fraction is
bound to cellular proteins or remain in the endocy-
totic pathway. It is also possible that cationic lipids
augment the production of nucleases which degrade
the Rz. Our results suggest that cationic liposome–Rz
complexes are sequestered in intracellular
membrane-bound compartments, such as endosomes,
similar to the fate of cationic liposome–DNA com-
w xplexes 51 . Such sequestering, together with the low
efficiency of cytoplasmic delivery could diminish the
potential effectiveness of the Rz, especially in chroni-
cally infected cells producing high quantities of virus.
Although we have utilized four cationic liposome
formulations and two Rz:lipid ratios in our studies, it
is possible that a more extensive matrix of Rz and
lipid concentrations may enhance the cytoplasmic
delivery of exogeneous Rz.
It will be of interest to investigate whether endo-
some disrupting peptides, such as those used to en-
hance the expression of transferrinrpolylysine-com-
w xplexed DNA 52 , or transferrin–cationic liposome
w xcomplexes 53 will facilitate the delivery of Rz into
the cytoplasm. We have shown that peptides that
interact with and destabilize membranes at mildly
acidic pH enhance gene delivery by cationic lipo-
w xsomes 54 . Likewise, the intracellular delivery of Rz
in pH-sensitive liposomes, which are thought to
destabilize the endosome membrane at the mildly
w xacidic pH of the endosome lumen 55,56 , may result
in enhanced cytoplasmic delivery. Preliminary exper-
iments in our laboratory have shown that the Rz used
in this study is effective in inhibiting HIV production
by macrophages when delivered in pH-sensitive lipo-
somes N. Duzgunes¸, E. Pretzer and S. Simoes, un-¨ ¨ ˜
.published data . The recent development of sterically
stabilized pH-sensitive liposomes with a prolonged
w xcirculation half-life 57 may render feasible the in
vivo delivery of Rz to target cells and tissues.
Differentiated THP-1rHIV-1 cells were moreIIIB
sensitive to cytotoxic effects of liposome–Rz com-
plexes than differentiated THP-1 cells. Interestingly,
the formation of complexes with Rz significantly
changes the toxic effect of liposomes alone. For
example, a 4-h treatment of differentiated THP-1
cells with the Lipofectamine–Rz complex at 8 mM
 .lipid caused a decrease in cell viability Fig. 3 , while
8 mM Lipofectamine alone was not toxic even after a
w x q24-h treatment 39 . HeLa CD4 cells were more
susceptible to cytotoxic effects of liposome–Rz com-
plexes than uninfected THP-1 cells, chronically in-
fected THP-1rHIV-1 cells or HeLarLAV cells.IIIB
These data are consistent with previous observations
that both the efficiency of cationic lipid-mediated
transfection and the toxicity of lipids or lipid–DNA
complexes, vary for different cell types
w x20,24,26,51,58,59 .
In summary our results indicate that the effective
delivery of functional Rz into cells by cationic lipo-
somes is an inefficient process and needs extensive
improvement before the technique can be used suc-
cessfully in ex vivo and in vivo applications. Viral
targets such as HIV, especially in chronically infected
cells, may not be as well suited for exogenous Rz
delivery as are intracellular targets present in smaller
molar amounts. It is possible that delivery of gene
constructs for continuous endogenous expression of
the Rz is a more promising strategy.
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